SCHEMBL25759529

SCHEMBL25759529

CCOC(=O)CCCCCOc1ccc(NC(=O)c2c[nH]cn2)cc1S(=O)(=O)Nc1ccc(Br)cc1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
KMT2A Q03164 11/20 0.44
MEN1 O00255 10/20 0.44
LMNA P02545 7/20 0.44
HTT P42858 5/20 0.44
ALDH1A1 P00352 5/20 0.43
GAA P10253 2/20 0.43
ALOX12 P18054 1/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
IDH1 O75874 2/20 0.41
HPGD P15428 1/20 0.39
NHERF1 O14745 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23833769 0.88 KMT2A (0.46) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL23833713 0.87 KMT2A (0.47) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL23846358 0.83 MAPT (0.43) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL23846462 0.80 MAPT (0.49) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL23833751 0.77 TBXA2R (0.47) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL23833757 0.77 SIRT2 (0.39) MAPTSMN1; SMN2LMNAHTTALDH1A1
SCHEMBL25759555 0.75 NPC1 (0.43) MAPTSMN1; SMN2KMT2AHTTALDH1A1
SCHEMBL23846419 0.73 KMT2A (0.52) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL23846321 0.73 KMT2A (0.51) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL25755498 0.66 KMT2A (0.62) MAPTSMN1; SMN2KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 MAPT 89/4885SMN1; SMN2 405/4885KMT2A 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.